Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating niraparib plus abiraterone and prednisone versus abiraterone alone in HRR gene-mutated metastatic castration-sensitive prostate cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Niraparib (Niraparib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Castration-sensitive Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-22